Two views on HDCT-ABMT breast cancer treatment controversy. Too experimental for insurers--or just too expensive?
Carter
R D
RD
Coleman
D M
DM
Bennett
J E
JE
D016026:Bone Marrow Transplantation / Q000191:economics*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000191:economics* / Q000601:surgery; D003363:Cost Control / Q000379:methods; D004358:Drug Therapy / Q000191:economics*; D004991:Ethics, Institutional; D005260:Female; D006801:Humans; D007343:Insurance Carriers / Q000191:economics / Q000592:standards; D007349:Insurance, Health, Reimbursement / Q000331:legislation & jurisprudence*; D010344:Patient Advocacy / Q000331:legislation & jurisprudence*; D014182:Transplantation, Autologous / Q000191:economics; D014481:United States